DPP4 and Hypertension: Hypertension was the most common comorbidity in the enrolled population; after propensity score weighting, 22 369 patients (84.20%) in the DPP-4 inhibitor group and 506 (83.92%) in the GLP-1 receptor agonist group had hypertension.